TVTX FDA decision — Apr 13, 2026
✓ APPROVED
Travere Therapeutics Inc. — FILSPARI (sparsentan) · Focal segmental glomerulosclerosis (FSGS).
Run-up into the decision (T-120 → T+5) PDUFA 4/13/26 $40.28 $26.79 10/27/25 Daily close, T-120 (10/27/25) through T+5. Run-up high $40.28 on 12/31/25, low $26.79 on 3/25/26 (T-120 to T-1). FDA decision 4/13/26. Historical price action, not a forecast.
Key facts
FDA decision date 2026-04-13
Outcome Approved
Drug / candidate FILSPARI (sparsentan)
Company Travere Therapeutics Inc.
120-day run-up (T-120→T-1) +6.0%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio